This drug may cause drowsiness, dizziness, and/or blurred vision, if affected, do not drive or operate machinery.
Obtain FEV1, FVC, and/or other pulmonary function tests, serum K, blood glucose. Monitor heart rate, blood pressure and signs of CNS stimulation.
Indacaterol: May potentiate hypokalaemic effect with xanthine derivatives, steroids, diuretics. May potentiate CV effects with MAOIs, TCA, QTc-prolonging agents. May cause sever bronchospasm with β-blockers.
Glycopyrronium: Increased adverse effects with other anticholinergic drugs.
Description: Indacaterol is a long acting beta2- agonist that acts locally in the lungs and relaxes bronchial smooth muscle.
Glycopyrronium is a long acting muscarinic receptor antagonist. It causes bronchodilatation by inhibiting the acetylcholine at muscarinic receptor subtypes 1-3 in bronchial smooth muscles. Onset: Within 5 minutes. Pharmacokinetics: Absorption: Indacaterol: Absolute bioavailability: 43-45%. Time to peak plasma concentration: Approx 15 minutes.
Glycopyrronium: Poorly absorbed from the gastrointestinal tract. Bioavailability: Approx 10-25%. Time to peak plasma concentration: Approx 5 minutes. Distribution: Indacaterol: Plasma protein binding: Approx 95%.
Glycopyrronium: Crosses blood-brain barrier (poorly). Volume of distribution: 83 L. Plasma protein binding: 38-41%. Metabolism: Indacaterol: Metabolised by CYP3A4 isoenzyme and via glucuronidation by uridine diphosphate-glucuronosyltransferase (UGT) 1A1. Excretion: Indacaterol: Via faeces (54% as unchanged drug, 23% as metabolites); urine. Elimination half-life: 40-56 hours.
Glycopyrronium: Via faeces; urine (23% as parent drug). Terminal elimination half-life: 33-57 hours.
Store between 15-25°C. Protect from light and moisture.
R03AL04 - indacaterol and glycopyrronium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Anon. Indacaterol and Glycopyrrolate. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/03/2018.Buckingham R (ed). Glycopyrronium Bromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2018.Buckingham R (ed). Indacaterol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2018.Joint Formulary Committee. Glycopyrronium with Indacaterol. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/03/2018.Utibron Neohaler Capsule (Novartis Pharmaceuticals Corporation). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 06/03/2018.